| Sep 13 |
Gilead Stock Rises as HIV Prevention Injection Meets Study Goals
|
| Sep 13 |
Subcutaneous Tecentriq gets FDA OK; Gilead shot succeeds in second HIV trial
|
| Sep 12 |
Why Gilead Sciences Stock Thrashed the Market Today
|
| Sep 12 |
Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention
|
| Sep 12 |
Gilead Sciences goes ex-dividend tomorrow
|
| Sep 12 |
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections
|
| Sep 12 |
Gilead Unveils More Positive Data on HIV Prevention Shot
|
| Sep 12 |
Gilead Stock Rises on Positive Study Results for Twice-Yearly HIV Drug
|
| Sep 12 |
Gilead says HIV prevention injection reduced cases by 96%, sending shares higher
|
| Sep 12 |
Helping End HIV - Gilead Sciences
|
